Idera Pharmaceuticals Phase 2 Results for Renal Cell Carcinoma Therapy

Business of Biotech

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced final data results from a clinical trial evaluating IMO-2055, a monotherapy in patients with Renal Cell Carcinoma. Progression-free survival medians for treatment-naïve patients were 4.5 months at 0.16 mg/kg/week and 1.9 months at 0.64 mg/kg/week.  The most common adverse events included fatigue, nausea, chills, headache, and pyrexia.

Business of Biotech  |  Email This Post  |  Printer Friendly
Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>